Christophe Marguet

Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with Cystic Fibrosis

P. Reix, P. Burgel, C. Marguet, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Inhalation treatment: Errors in application and difficulties in acceptance of the devices are frequent in wheezy infants and young children

C. Marguet, P. Le Roux, L. Couderc, 2001, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.

S. Urien, N. Bouazza, J. Treluyer, 2024, Clinical pharmacokinetics.

Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis

H. Corvol, S. Benaboud, F. Chédevergne, 2024, The Lancet.